Company
Neurocrine Biosciences
NASDAQ:NBIX
Neurocrine Biosciences incorporated in January 1992, is engaged in developing, discovering and commercializing drugs for the treatment of neurological and endocrine-related diseases and disorders.
5 stories
Voyager Therapeutics sells gene therapy programs to Neurocrine Biosciences for $165M
Under the deal’s terms, Neurocrine will pay Voyager in cash, which includes $115 million upfront and a $50 million equity investment
Investments and investor services
EARLY MOVERS: Neurocrine Biosciences stock slumps after Tourette drug test fails
Mallinckrodt shares fall after its painkiller treatment was declined by the US Food and Drug Administration
Oppenheimer raises price target for Neurocrine Biosciences
The analysts were bullish on the San Diego biotech’s expansion, outlook and potential for new drug sales
Neurocrine Biosciences shoots up on INGREZZA FDA approval news
The FDA has approved INGREZZA (valbenazine) capsules for the treatment of adults with tardive dyskinesia (TD).